Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BMEA 
Biomea Fusion Inc (BMEA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: BMEA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.29
1 Year Target Price $7.29
| 4 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -18.96% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 114.26M USD | Price to earnings Ratio - | 1Y Target Price 7.29 |
Price to earnings Ratio - | 1Y Target Price 7.29 | ||
Volume (30-day avg) 9 | Beta -0.16 | 52 Weeks Range 1.29 - 13.07 | Updated Date 08/29/2025 |
52 Weeks Range 1.29 - 13.07 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3 |
Earnings Date
Report Date 2025-08-05 | When - | Estimate -0.54 | Actual -0.51 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -68.73% | Return on Equity (TTM) -170.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 65086354 | Price to Sales(TTM) - |
Enterprise Value 65086354 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.75 | Shares Outstanding 59508500 | Shares Floating 47423528 |
Shares Outstanding 59508500 | Shares Floating 47423528 | ||
Percent Insiders 9.47 | Percent Institutions 48.39 |
Upturn AI SWOT
Biomea Fusion Inc
Company Overview
History and Background
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel irreversible small molecules to treat genetically defined cancers and metabolic diseases. Founded in 2018, it emerged from research focusing on covalent binding mechanisms. Its early milestones involve securing funding and advancing its lead program, BMF-219, into clinical trials.
Core Business Areas
- Drug Discovery and Development: Focuses on discovering and developing irreversible small molecule drugs targeting difficult-to-treat diseases. This includes research, preclinical studies, and clinical trials.
- Oncology: Develops therapies for genetically defined cancers where irreversible binding offers a therapeutic advantage.
- Metabolic Diseases: Develops therapies for metabolic diseases, with a focus on Type 2 Diabetes.
Leadership and Structure
Biomea Fusion is led by a management team with expertise in drug development and business strategy. The organizational structure includes departments for research, development, clinical operations, and finance.
Top Products and Market Share
Key Offerings
- BMF-219: BMF-219 is Biomea Fusion's lead investigational drug, an orally administered covalent menin inhibitor being evaluated for the treatment of Type 2 Diabetes (T2D). Clinical trials are ongoing. There is no current market share as it is an investigational drug. Competitors developing diabetes treatments include Novo Nordisk (NVO) and Eli Lilly (LLY).
- Covalent Menin Inhibitors (Oncology Programs): Biomea Fusion is developing covalent menin inhibitors for genetically defined cancers. These programs are in preclinical stages. There is no current market share as it is an investigational drug. Competitors are those developing other oncology therapies that target similar genetic pathways.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with significant investment in research and development. The market for diabetes and oncology drugs is substantial and growing, driven by increasing prevalence of these diseases.
Positioning
Biomea Fusion is positioned as an innovator in developing irreversible small molecule drugs. Its competitive advantage lies in its proprietary technology and focus on specific genetic targets.
Total Addressable Market (TAM)
The TAM for diabetes and oncology treatments is very large, estimated to be hundreds of billions of dollars globally. Biomea Fusion is positioning itself to capture a portion of this market with its targeted therapies, however at present has no market share.
Upturn SWOT Analysis
Strengths
- Novel irreversible small molecule technology platform
- Strong intellectual property portfolio
- Experienced management team
- Focus on genetically defined diseases
Weaknesses
- Early-stage clinical development (high risk)
- Reliance on single lead compound (BMF-219)
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on successful clinical trial outcomes
Opportunities
- Potential to address unmet needs in diabetes and oncology
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline with new drug candidates
- Positive clinical trial results leading to regulatory approvals
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- Novo Nordisk (NVO)
- Eli Lilly (LLY)
- Merck (MRK)
Competitive Landscape
Biomea Fusion's competitive advantage lies in its unique irreversible binding technology. However, it faces significant competition from established pharmaceutical companies with greater resources and broader pipelines. The market share comparison is focused on the diabetes market and will change as the company moves into oncology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical development and advancement into clinical trials.
Future Projections: Future growth depends on the successful completion of clinical trials for BMF-219 and other pipeline candidates, as well as potential partnerships and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing BMF-219 in clinical trials for Type 2 Diabetes and continuing preclinical development of oncology programs.
Summary
Biomea Fusion is a clinical-stage biopharmaceutical company with a novel technology platform and a focus on genetically defined diseases. Its lead program, BMF-219, is currently in clinical trials for Type 2 Diabetes. While it shows promise, Biomea Fusion faces challenges including clinical trial risks, competition from larger companies, and reliance on successful clinical trial outcomes. The company's future growth depends on the successful development and commercialization of its drug candidates.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is based on available estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biomea Fusion Inc
Exchange NASDAQ | Headquaters San Carlos, CA, United States | ||
IPO Launch date 2021-04-16 | Interim CEO & Director Dr. Michael J. M. Hitchcock Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 63 | Website https://biomeafusion.com |
Full time employees 63 | Website https://biomeafusion.com | ||
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in San Carlos, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.